Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Have Completed a Prior Clinical Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.
This is a Phase II, non-randomized, open-label, single arm, continuation trial.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
City of Hope National Medical Center
Duarte, California, United States
University of Florida
Gainesville, Florida, United States
University of Chicago
Chicago, Illinois, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Royal Marsden Hospital
Sutton, United Kingdom
Start Date
April 1, 2004
Primary Completion Date
September 1, 2006
Completion Date
September 1, 2006
Last Updated
November 18, 2019
2
ACTUAL participants
FK228 (romidepsin)
DRUG
Lead Sponsor
Celgene
NCT07225946
NCT07227415
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04868604